Other Events ·
Gain Therapeutics, Inc. announced that its current cash and cash equivalents are expected to fund operations into the…
GANXGain Therapeutics, Inc.
Gain Therapeutics, Inc. announced that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027. This funding includes the completion of the Phase 1b open-label extension in October 2026 and the initiation of a Phase 2 clinical study in the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and other diseases.